Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2022 | Apr. 25, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-35092 | |
Entity Registrant Name | EXACT SCIENCES CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 02-0478229 | |
Entity Address, Address Line One | 5505 Endeavor Lane | |
Entity Address, City or Town | Madison | |
Entity Address, State or Province | WI | |
Entity Address, Postal Zip Code | 53719 | |
City Area Code | 608 | |
Local Phone Number | 535-8815 | |
Title of 12(b) Security | Common Stock, $0.01 par value per share | |
Trading Symbol | EXAS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 175,945,110 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001124140 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash and cash equivalents | $ 189,776 | $ 315,471 |
Marketable securities | 627,204 | 715,005 |
Accounts receivable, net | 205,625 | 216,645 |
Inventory | 112,958 | 104,994 |
Prepaid expenses and other current assets | 79,575 | 74,122 |
Total current assets | 1,215,138 | 1,426,237 |
Long-term Assets: | ||
Property, plant and equipment, net | 622,613 | 580,248 |
Operating lease right-of-use assets | 170,373 | 174,225 |
Goodwill | 2,335,172 | 2,335,172 |
Intangible assets, net | 2,069,757 | 2,094,411 |
Other long-term assets, net | 77,484 | 74,591 |
Total assets | 6,490,537 | 6,684,884 |
Current Liabilities: | ||
Accounts payable | 66,471 | 67,829 |
Accrued liabilities | 365,916 | 398,556 |
Operating lease liabilities, current portion | 19,711 | 19,710 |
Other current liabilities | 28,854 | 30,973 |
Total current liabilities | 480,952 | 517,068 |
Long-term Liabilities: | ||
Convertible notes, net | 2,181,680 | 2,180,232 |
Other long-term liabilities | 389,062 | 417,782 |
Operating lease liabilities, less current portion | 180,632 | 182,166 |
Total liabilities | 3,232,326 | 3,297,248 |
Commitments and contingencies (Note 14) | ||
Stockholders’ Equity: | ||
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at March 31, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—175,551,408 and 173,674,067 shares at March 31, 2022 and December 31, 2021 | 1,757 | 1,738 |
Additional paid-in capital | 6,085,558 | 6,028,861 |
Accumulated other comprehensive loss | (6,647) | (1,443) |
Accumulated deficit | (2,822,457) | (2,641,520) |
Total stockholders’ equity | 3,258,211 | 3,387,636 |
Total liabilities and stockholders’ equity | $ 6,490,537 | $ 6,684,884 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 400,000,000 | 400,000,000 |
Common stock, issued (in shares) | 175,551,408 | 173,674,067 |
Common stock, outstanding (in shares) | 175,551,408 | 173,674,067 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Statement [Abstract] | ||
Revenue | $ 486,571 | $ 402,077 |
Operating expenses | ||
Cost of sales (exclusive of amortization of acquired intangible assets) | 134,705 | 109,993 |
Research and development | 102,248 | 115,567 |
Sales and marketing | 232,181 | 186,141 |
General and administrative | 169,770 | 267,727 |
Amortization of acquired intangible assets | 24,654 | 23,190 |
Total operating expenses | 663,558 | 702,618 |
Loss from operations | (176,987) | (300,541) |
Other income (expense) | ||
Investment income (expense), net | (1,487) | 31,188 |
Interest expense | (4,478) | (4,616) |
Total other income (expense) | (5,965) | 26,572 |
Net loss before tax | (182,952) | (273,969) |
Income tax benefit | 2,015 | 242,805 |
Net loss | $ (180,937) | $ (31,164) |
Net loss per share - basic (in usd per share) | $ (1.04) | $ (0.18) |
Net loss per share - diluted (in usd per share) | $ (1.04) | $ (0.18) |
Weighted average common shares outstanding - basic (in shares) | 174,417 | 169,434 |
Weighted average common shares outstanding - diluted (in shares) | 174,417 | 169,434 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (180,937) | $ (31,164) |
Other comprehensive income (loss), before tax: | ||
Unrealized loss on available-for-sale investments | (4,967) | (332) |
Foreign currency translation loss | (237) | 0 |
Comprehensive loss, before tax | (186,141) | (31,496) |
Income tax benefit related to items of other comprehensive loss | 0 | 170 |
Comprehensive loss, net of tax | $ (186,141) | $ (31,326) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Balance (in shares) at Dec. 31, 2020 | 159,423,410 | ||||
Beginning balance at Dec. 31, 2020 | $ 2,235,552 | $ 1,595 | $ 4,279,327 | $ 526 | $ (2,045,896) |
Increase (Decrease) in Stockholders' Equity | |||||
Settlement of convertible notes, net of tax (in shares) | 344 | ||||
Settlement of convertible notes, net of tax | $ 26 | 26 | |||
Exercise of common stock options (in shares) | 967,107 | ||||
Exercise of common stock options | 8,759 | $ 10 | 8,749 | ||
Issuance of common stock to fund the Company's 401(k) match (in shares) | 162,606 | ||||
Issuance of common stock to fund the Company's 401(k) match | 22,934 | $ 2 | 22,932 | ||
Compensation expense related to issuance of stock options and restricted stock awards (in shares) | 1,355,435 | ||||
Compensation expense related to issuance of stock options and restricted stock awards | 158,252 | $ 13 | 158,239 | ||
Issuance of common stock for business combinations, net of issuance costs (in shares) | 9,384,410 | ||||
Issuance of common stock for business combinations, net of issuance costs | 1,254,798 | $ 94 | 1,254,704 | ||
Net loss | (31,164) | (31,164) | |||
Other comprehensive income (loss) | (162) | (162) | |||
Balance (in shares) at Mar. 31, 2021 | 171,293,312 | ||||
Ending balance at Mar. 31, 2021 | $ 3,648,995 | $ 1,714 | 5,723,977 | 364 | (2,077,060) |
Balance (in shares) at Dec. 31, 2021 | 173,674,067 | 173,674,067 | |||
Beginning balance at Dec. 31, 2021 | $ 3,387,636 | $ 1,738 | 6,028,861 | (1,443) | (2,641,520) |
Increase (Decrease) in Stockholders' Equity | |||||
Exercise of common stock options (in shares) | 485,537 | ||||
Exercise of common stock options | 4,282 | $ 5 | 4,277 | ||
Compensation expense related to issuance of stock options and restricted stock awards (in shares) | 1,391,797 | ||||
Compensation expense related to issuance of stock options and restricted stock awards | 52,441 | $ 14 | 52,427 | ||
Other (in shares) | 7 | ||||
Other | (7) | (7) | |||
Net loss | (180,937) | (180,937) | |||
Other comprehensive income (loss) | $ (5,204) | (5,204) | |||
Balance (in shares) at Mar. 31, 2022 | 175,551,408 | 175,551,408 | |||
Ending balance at Mar. 31, 2022 | $ 3,258,211 | $ 1,757 | $ 6,085,558 | $ (6,647) | $ (2,822,457) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders Equity (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 |
Statement of Financial Position [Abstract] | |||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (180,937) | $ (31,164) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 22,993 | 20,508 |
Loss on disposal of property, plant and equipment | 321 | 337 |
Unrealized (gain) loss on equity investments | 1,350 | (7) |
Deferred tax benefit | (1,912) | (243,130) |
Stock-based compensation | 52,441 | 77,292 |
Post-combination expense for acceleration of unvested equity | 0 | 80,960 |
Realized gain on preferred stock investment | 0 | (30,500) |
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities | 1,700 | 1,633 |
Amortization of premium on short-term investments | 956 | 439 |
Amortization of acquired intangible assets | 24,654 | 23,190 |
Asset acquisition IPR&D expense | 0 | 52,263 |
Remeasurement of contingent consideration | (26,680) | 2,879 |
Non-cash lease expense | 7,363 | 5,740 |
Changes in assets and liabilities: | ||
Accounts receivable, net | 11,020 | (22,950) |
Inventory, net | (7,964) | 3,232 |
Operating lease liabilities | (5,177) | (3,120) |
Accounts payable and accrued liabilities | (66,048) | (15,862) |
Other assets and liabilities | (7,834) | 1,033 |
Net cash used in operating activities | (173,754) | (77,227) |
Cash flows from investing activities: | ||
Purchases of marketable securities | (70,267) | (162,498) |
Maturities and sales of marketable securities | 150,630 | 236,295 |
Purchases of property, plant and equipment | (33,623) | (12,920) |
Business combination, net of cash acquired | 0 | (343,248) |
Asset acquisition | 0 | (25,000) |
Investments in privately held companies | (1,172) | (10,000) |
Other investing activities | (7) | (141) |
Net cash provided by (used in) investing activities | 45,561 | (317,512) |
Cash flows from financing activities: | ||
Proceeds from exercise of common stock options | 4,282 | 8,759 |
Other financing activities | (1,547) | (1,514) |
Net cash provided by financing activities | 2,735 | 7,245 |
Effects of exchange rate changes on cash and cash equivalents | (237) | 0 |
Net decrease in cash, cash equivalents and restricted cash | (125,695) | (387,494) |
Cash, cash equivalents and restricted cash, beginning of period | 315,768 | 1,491,594 |
Cash, cash equivalents and restricted cash, end of period | 190,073 | 1,104,100 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Property, plant and equipment acquired but not paid | 31,491 | 8,697 |
Business combination contingent consideration liability | 0 | 331,348 |
Supplemental disclosure of cash flow information: | ||
Interest paid | $ 5,133 | $ 5,274 |
Condensed Consolidated Statem_6
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Cash Flows [Abstract] | ||||
Cash and cash equivalents | $ 189,776 | $ 315,471 | $ 1,103,816 | |
Restricted cash — included in other long-term assets, net | 297 | 297 | 284 | |
Total cash, cash equivalents and restricted cash | $ 190,073 | $ 315,768 | $ 1,104,100 | $ 1,491,594 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world. Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements, which include the accounts of Exact Sciences Corporation and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “2021 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2021 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2021 Form 10-K. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report and the 2021 Form 10-K. The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, marketable and non-marketable investments, software, and the carrying value of the goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. The pandemic and related precautionary measures began to materially disrupt the Company's operations in March 2020 and may continue to disrupt the business for an unknown period of time. As a result, the pandemic had an impact on the Company’s revenues and operating results. The ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity. Significant Accounting Policies During the three months ended March 31, 2022, there were no changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, except as described in the Recently Adopted Accounting Pronouncements section below. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In October 2021, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company early adopted the amendments in this update during the first quarter of fiscal year 2022. There was no material impact to the Company’s condensed consolidated financial statements. Net Loss Per Share Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses. The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period: March 31, (In thousands) 2022 2021 Shares issuable in connection with acquisitions (1) 45 157 Shares issuable upon exercise of stock options 1,790 2,633 Shares issuable upon the release of restricted stock awards 6,991 4,467 Shares issuable upon the release of performance share units 963 846 Shares issuable upon conversion of convertible notes 20,309 20,309 30,098 28,412 ______________ |
REVENUE
REVENUE | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE | REVENUE The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype DX, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Disaggregation of Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, (In thousands) 2022 2021 Screening Medicare Parts B & C $ 113,755 $ 101,559 Commercial 161,680 127,874 Other 31,087 10,895 Total Screening 306,522 240,328 Precision Oncology Medicare Parts B & C $ 52,565 $ 44,837 Commercial 46,062 46,812 International 29,443 26,056 Other 24,550 11,702 Total Precision Oncology 152,620 129,407 COVID-19 Testing $ 27,429 $ 32,342 Total $ 486,571 $ 402,077 Screening revenue primarily includes laboratory service revenue from the Cologuard test while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype® products. Revenue recognized from changes in transaction price was $4.2 million and $1.7 million for the three months ended March 31, 2022 and 2021, respectively. The Company had deferred revenue of $1.3 million and $1.0 million as of March 31, 2022 and December 31, 2021, respectively. Deferred revenue is reported in other current liabilities in the Company’s condensed consolidated balance sheets. Revenue recognized for the three months ended March 31, 2022 and 2021, which was included in the deferred revenue balance at the beginning of each period, was $0.3 million and $14.0 million, respectively. Of the $14.0 million of revenue recognized for the three months ended March 31, 2021, which was included in the deferred revenue balance at the beginning of the period, $13.8 million related to COVID-19 testing. |
MARKETABLE SECURITIES
MARKETABLE SECURITIES | 3 Months Ended |
Mar. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
MARKETABLE SECURITIES | MARKETABLE SECURITIES The following table sets forth the Company’s cash, cash equivalents, restricted cash, and marketable securities at March 31, 2022 and December 31, 2021: (In thousands) March 31, 2022 December 31, 2021 Cash, cash equivalents, and restricted cash Cash and money market $ 135,320 $ 247,335 Cash equivalents 54,456 68,136 Restricted cash 297 297 Total cash, cash equivalents, and restricted cash 190,073 315,768 Marketable securities Available-for-sale debt securities $ 625,383 $ 711,669 Equity securities 1,821 3,336 Total marketable securities 627,204 715,005 Total cash and cash equivalents, restricted cash and marketable securities $ 817,277 $ 1,030,773 Available-for-sale debt securities at March 31, 2022 consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Losses in Accumulated Estimated Fair Cash equivalents Commercial paper $ 51,979 $ — $ — $ 51,979 U.S. government agency securities 2,477 — — 2,477 Total cash equivalents 54,456 — — 54,456 Marketable securities Corporate bonds $ 229,768 $ — $ (1,952) $ 227,816 U.S. government agency securities 250,764 — (3,594) 247,170 Certificates of deposit 41,204 — (50) 41,154 Commercial paper 12,924 — (4) 12,920 Asset backed securities 97,156 — (833) 96,323 Total marketable securities 631,816 — (6,433) 625,383 Total available-for-sale securities $ 686,272 $ — $ (6,433) $ 679,839 ______________ (1) Gains and losses in accumulated other comprehensive income (loss) (“AOCI”) are reported before tax impact. Available-for-sale debt securities at December 31, 2021 consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Losses in Accumulated Estimated Fair Value Cash equivalents U.S. government agency securities $ 3,543 $ — $ — $ 3,543 Commercial paper 64,593 — — 64,593 Total cash equivalents 68,136 — — 68,136 Marketable securities U.S. government agency securities $ 250,793 $ — $ (873) $ 249,920 Asset backed securities 94,565 2 (107) 94,460 Commercial paper 6,996 — — 6,996 Certificates of deposit 47,147 2 (10) 47,139 Corporate bonds 313,634 13 (493) 313,154 Total marketable securities 713,135 17 (1,483) 711,669 Total available-for-sale securities $ 781,271 $ 17 $ (1,483) $ 779,805 ______________ (1) Gains and losses in AOCI are reported before tax impact. The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2022: Due one year or less Due after one year through five years (In thousands) Cost Fair Value Cost Fair Value Cash equivalents Commercial paper $ 51,979 $ 51,979 $ — $ — U.S. government agency securities 2,477 2,477 — — Total cash equivalents 54,456 54,456 — — Marketable securities U.S. government agency securities $ 134,099 $ 132,683 $ 116,665 $ 114,487 Corporate bonds 114,973 114,482 114,795 113,334 Certificates of deposit 41,204 41,154 — — Asset backed securities — — 97,156 96,323 Commercial paper 12,924 12,920 — — Total marketable securities 303,200 301,239 328,616 324,144 Total $ 357,656 $ 355,695 $ 328,616 $ 324,144 The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than one year One year or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities Corporate bonds $ 216,816 $ (1,952) $ — $ — $ 216,816 $ (1,952) Certificates of deposit 41,154 (50) — — 41,154 (50) Asset backed securities 96,324 (833) — — 96,324 (833) U.S. government agency securities 247,170 (3,594) — — 247,170 (3,594) Commercial paper 3,989 (4) — — 3,989 (4) Total available-for-sale securities $ 605,453 $ (6,433) $ — $ — $ 605,453 $ (6,433) The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2022 and December 31, 2021, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. |
INVENTORY
INVENTORY | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
INVENTORY | INVENTORY Inventory consisted of the following: (In thousands) March 31, 2022 December 31, 2021 Raw materials $ 55,402 $ 51,321 Semi-finished and finished goods 57,556 53,673 Total inventory $ 112,958 $ 104,994 |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT | PROPERTY, PLANT AND EQUIPMENT The carrying value and estimated useful lives of property, plant and equipment are as follows: (In thousands) Estimated Useful Life March 31, 2022 December 31, 2021 Property, plant and equipment Land n/a $ 4,716 $ 4,716 Leasehold and building improvements (1) 166,286 147,083 Land improvements 15 years 5,206 5,206 Buildings 30 - 40 years 210,439 210,560 Computer equipment and computer software 3 years 117,393 109,119 Laboratory equipment 3 - 10 years 202,104 189,748 Furniture and fixtures 3 - 10 years 29,727 28,293 Assets under construction n/a 123,873 100,339 Property, plant and equipment, at cost 859,744 795,064 Accumulated depreciation (237,131) (214,816) Property, plant and equipment, net $ 622,613 $ 580,248 ______________ (1) Lesser of remaining lease term, building life, or estimated useful life. Depreciation expense for the three months ended March 31, 2022 and 2021 was $23.0 million and $20.5 million, respectively. |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS AND GOODWILL | INTANGIBLE ASSETS AND GOODWILL Intangible Assets The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2022: (In thousands) Weighted Average Remaining Life (Years) Gross Carrying Amount Accumulated Amortization Net Balance at March 31, 2022 Finite-lived intangible assets Trade name 13.2 $ 104,700 $ (15,378) $ 89,322 Customer relationships 9.4 6,700 (1,712) 4,988 Patents 3.4 10,942 (7,110) 3,832 Acquired developed technology 8.4 918,171 (198,649) 719,522 Supply agreements 5.2 2,295 (202) 2,093 Total finite-lived intangible assets 1,042,808 (223,051) 819,757 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (223,051) $ 2,069,757 The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2021: (In thousands) Weighted Average Remaining Life (Years) Gross Carrying Amount Accumulated Amortization Net balance at December 31, 2021 Finite-lived intangible assets Trade name 13.4 $ 104,700 $ (13,554) $ 91,146 Customer relationships 9.6 6,700 (1,577) 5,123 Patents and licenses 3.6 10,942 (6,763) 4,179 Acquired developed technology 8.6 918,171 (176,402) 741,769 Supply agreements 5.4 2,295 (101) 2,194 Total finite-lived intangible assets 1,042,808 (198,397) 844,411 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (198,397) $ 2,094,411 As of March 31, 2022, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows: (In thousands) 2022 (remaining nine months) $ 73,962 2023 98,611 2024 98,276 2025 97,228 2026 96,169 Thereafter 355,511 $ 819,757 The Company’s acquired intangible assets are being amortized on a straight-line basis over the estimated useful life. Goodwill The change in the carrying amount of goodwill for the periods ended March 31, 2022 and December 31, 2021 is as follows: (In thousands) Balance, January 1, 2021 $ 1,237,672 Thrive acquisition 948,105 Ashion acquisition 56,758 PreventionGenetics acquisition 92,637 Balance, December 31, 2021 2,335,172 Balance March 31, 2022 $ 2,335,172 There were no impairment losses for the three months ended March 31, 2022 and 2021. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The three levels of the fair value hierarchy established are as follows: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available. The following table presents the Company’s fair value measurements as of March 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at March 31, 2022 Quoted Prices Significant Other Significant Cash, cash equivalents, and restricted cash Cash and money market $ 135,320 $ 135,320 $ — $ — Commercial paper 51,979 — 51,979 — U.S. government agency securities 2,477 — 2,477 — Restricted cash 297 297 — — Marketable securities Corporate bonds $ 227,816 $ — $ 227,816 $ — Certificates of deposit 41,154 — 41,154 — Commercial paper 12,920 — 12,920 — U.S. government agency securities 247,170 — 247,170 — Asset backed securities 96,323 — 96,323 — Equity securities 1,821 1,821 — — Non-marketable securities $ 2,640 $ — $ — $ 2,640 Liabilities Contingent consideration $ (332,341) $ — $ — $ (332,341) Total $ 487,576 $ 137,438 $ 679,839 $ (329,701) The following table presents the Company’s fair value measurements as of December 31, 2021 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at December 31, 2021 Quoted Prices Significant Other Significant Cash and cash equivalents Cash and money market $ 247,335 $ 247,335 $ — $ — Commercial paper 64,593 — 64,593 — U.S. government agency securities 3,543 — 3,543 — Restricted cash 297 297 — — Marketable securities U.S. government agency securities $ 249,920 $ — $ 249,920 $ — Corporate bonds 313,154 — 313,154 — Asset backed securities 94,460 — 94,460 — Certificates of deposit 47,139 — 47,139 — Commercial paper 6,996 — 6,996 — Equity securities 3,336 3,336 — — Non-marketable securities $ 3,090 $ — $ — $ 3,090 Liabilities Contingent consideration $ (359,021) $ — $ — $ (359,021) Total $ 674,842 $ 250,968 $ 779,805 $ (355,931) There have been no changes in valuation techniques or transfers between fair value measurement levels during the three months ended March 31, 2022. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors. Contingent Consideration The fair value of contingent consideration as of March 31, 2022 and December 31, 2021 was $332.3 million and $359.0 million, respectively, which was recorded in other long-term liabilities in the condensed consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: (In thousands) Contingent Consideration Beginning balance, January 1, 2022 $ 359,021 Changes in fair value (26,680) Ending balance, March 31, 2022 $ 332,341 This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones associated with the acquisitions of Thrive Earlier Detection Corporation (“Thrive”) and Ashion Analytics, LLC (“Ashion”) was $331.1 million and $357.8 million as of March 31, 2022 and December 31, 2021, respectively. The Company evaluates the fair value of the regulatory and product development milestones related expected contingent consideration and the corresponding liability using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 91% as of March 31, 2022 and December 31, 2021, respectively, and a weighted average present-value factor of 4.5% and 2.3% as of March 31, 2022 and December 31, 2021, respectively. The projected fiscal year of payment range is from 2024 to 2027. Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. The fair value of the contingent consideration earnout liability related to certain revenue milestones associated with the Biomatrica acquisition was $1.2 million as of March 31, 2022 and December 31, 2021. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone. Non-Marketable Equity Investments As of March 31, 2022 and December 31, 2021, the aggregate carrying amounts of the Company’s non-marketable equity securities without readily determinable fair values were $25.9 million and $25.3 million, respectively, which are classified as a component of other long-term assets in the Company’s condensed consolidated balance sheets. There have been no downward or upward adjustments made on these investments since initial recognition. The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $14.8 million remained callable through 2033 as of March 31, 2022. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets in the Company’s condensed consolidated balance sheets, were $2.7 million and $1.5 million as of March 31, 2022 and December 31, 2021, respectively. Derivative Financial Instruments As of March 31, 2022 and December 31, 2021, the Company had open foreign currency forward contracts with notional amounts of $48.9 million and $46.7 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the foreign currency forward contracts was zero at March 31, 2022 and December 31, 2021, and there were no gains or losses recorded for the three months ended March 31, 2022 and 2021. |
LONG-TERM DEBT
LONG-TERM DEBT | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
LONG-TERM DEBT | LONG-TERM DEBT Revolving Loan Agreement During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC Bank, National Association (“PNC”). The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding. Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. The Revolver’s maturity date is November 5, 2023. The Company has agreed in the Revolving Loan Agreement to various financial covenants, and as of March 31, 2022, the Company is in compliance with all covenants. |
CONVERTIBLE NOTES
CONVERTIBLE NOTES | 3 Months Ended |
Mar. 31, 2022 | |
CONVERTIBLE NOTES [Abstract] | |
CONVERTIBLE NOTES | CONVERTIBLE NOTES Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2022: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,074) $ 1,131,926 $ 1,032,125 2 2027 Convertible notes - 0.375% 747,500 (11,137) 736,363 712,315 2 2025 Convertible notes - 1.000% 315,005 (1,614) 313,391 377,833 2 Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2021: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,826) $ 1,131,174 $ 1,139,650 2 2027 Convertible notes - 0.375% 747,500 (11,691) 735,809 771,794 2 2025 Convertible notes - 1.000% 315,005 (1,756) 313,249 415,473 2 ______________ (1) The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. Summary of Conversion Features Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election. It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, and 8.21 shares of common stock per $1,000 principal amount for the convertible notes due in 2025 (“2025 Notes”), 2027 (“2027 Notes”), and 2028 (“2028 Notes”), respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, and $121.84 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, and 2028 Notes, respectively. The 2025 Notes, 2027 Notes, and 2028 Notes may be convertible in up to 4.2 million, 6.7 million, and 9.4 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate. If the Company undergoes a “fundamental change” (as defined in the Indenture), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest. Based on the closing price of the Company’s common stock of $69.92 on March 31, 2022, the if-converted values on the Notes do not exceed the principal amount. The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. Ranking of Convertible Notes The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Issuance Costs Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes: (In thousands) January 2025 Notes $ 10,284 June 2025 Notes 7,362 2027 Notes 14,285 2028 Notes 24,453 Interest Expense Interest expense includes the following: Three Months Ended March 31, (In thousands) 2022 2021 Debt issuance costs amortization $ 1,412 $ 1,413 Debt discount amortization 36 36 Coupon interest expense 2,567 2,567 Total interest expense on convertible notes 4,015 4,016 Other interest expense 463 600 Total interest expense $ 4,478 $ 4,616 The effective interest rates on the 2025 Notes, 2027 Notes, and 2028 Notes for the three months ended March 31, 2022 and 2021 were 1.18%, 0.67%, and 0.64% and 1.18%, 0.67%, and 0.64%, respectively. The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 2.80, 4.96, and 5.92 years for the 2025 Notes, 2027 Notes, and 2028 Notes, respectively. |
LICENSE AND COLLABORATION AGREE
LICENSE AND COLLABORATION AGREEMENTS | 3 Months Ended |
Mar. 31, 2022 | |
LICENSE AGREEMENTS [Abstract] | |
LICENSE AND COLLABORATION AGREEMENTS | LICENSE AND COLLABORATION AGREEMENTS The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees. Mayo In June 2009, the Company entered into a license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”). The Company’s license agreement with Mayo was most recently amended and restated in September 2020. Under the license agreement, Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property. Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement. As part of the most recent amendment, the Company agreed to pay Mayo an additional $6.3 million, payable in five equal annual installments through 2024. The annual installments are recorded in research and development expenses in the Company’s condensed consolidated statements of operations. The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement. In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company incurred charges of $1.4 million and $1.2 million for the three months ended March 31, 2022 and 2021, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations. Johns Hopkins University (“JHU”) Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with JHU for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, multi-cancer early detection test. The agreement terms include single-digit sales-based royalties and sales-based milestone payments of $10.0 million, $15.0 million, and $20.0 million upon achieving calendar year licensed product revenue using JHU proprietary data of $0.50 billion, $1.00 billion, and $1.50 billion, respectively. |
PFIZER PROMOTION AGREEMENT
PFIZER PROMOTION AGREEMENT | 3 Months Ended |
Mar. 31, 2022 | |
PFIZER PROMOTION AGREEMENT | |
PFIZER PROMOTION AGREEMENT | PFIZER PROMOTION AGREEMENTIn August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provides that the Company will pay Pfizer a total of $35.9 million in three installments during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company’s condensed consolidated statements of operations. Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred charges of $2.5 million and $22.7 million for the service fee for the three months ended March 31, 2022 and 2021, respectively. The Company incurred charges of $38.4 million and $26.6 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the three months ended March 31, 2022 and 2021, respectively. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY | STOCKHOLDERS’ EQUITY PreventionGenetics LLC (“PreventionGenetics”) Acquisition Stock Issuance In December 2021, the Company completed its acquisition of PreventionGenetics. In connection with the acquisition, which is further described in Note 16, the Company issued 1.1 million shares of the Company's common stock that had a fair value of $84.2 million. Ashion Acquisition Stock Issuance In April 2021, the Company completed its acquisition of Ashion. In connection with the acquisition, which is further described in Note 16, the Company issued 0.1 million shares of the Company’s common stock that had a fair value of $16.2 million. Thrive Acquisition Stock Issuance In January 2021, the Company completed its acquisition of Thrive. In connection with the acquisition, which is further described in Note 16, the Company issued 9.3 million shares of the Company’s common stock that had a fair value of $1.19 billion. Targeted Digital Sequencing (“TARDIS”) License Acquisition Stock Issuance In January 2021, the Company acquired a worldwide exclusive license to the TARDIS technology from The Translational Genomics Research Institute (“TGen”), which is further described in Note 16. As part of the consideration transferred, the Company issued 0.2 million shares of the Company’s common stock that had a fair value of $27.3 million. Exact Sciences 401(k) Plan As further discussed in Note 16 of the Company’s most recently filed Form 10-K, the Company maintains a qualified 401(k) retirement savings plan (the “401(k) Plan”) for Exact Sciences employees and matching contributions are made annually by the Company in the form of the Company’s common stock. The Company issued 0.4 million shares of the Company’s common stock to fund the Company’s 2021 401(k) match in April 2022. Changes in Accumulated Other Comprehensive Income (Loss) The amount recognized in AOCI for the three months ended March 31, 2022 were as follows: (In thousands) Foreign Currency Translation Adjustments Unrealized Accumulated Balance at December 31, 2021 $ 23 $ (1,466) $ (1,443) Other comprehensive loss before reclassifications (237) (4,994) (5,231) Amounts reclassified from accumulated other comprehensive loss — 27 27 Net current period change in accumulated other comprehensive loss (237) (4,967) (5,204) Balance at March 31, 2022 $ (214) $ (6,433) $ (6,647) ______________ (1) There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022. The amounts recognized in AOCI for the three months ended March 31, 2021 were as follows: (In thousands) Unrealized Accumulated Balance at December 31, 2020 $ 526 $ 526 Other comprehensive loss before reclassifications (292) (292) Amounts reclassified from accumulated other comprehensive income (40) (40) Net current period change in accumulated other comprehensive income, before tax (332) (332) Income tax benefit related to items of other comprehensive income 170 170 Balance at March 31, 2021 $ 364 $ 364 Amounts reclassified from AOCI for the three months ended March 31, 2022 and 2021 were as follows: Affected Line Item in the Three Months Ended March 31, Details about AOCI Components (In thousands) 2022 2021 Change in value of available-for-sale investments Sales and maturities of available-for-sale investments Investment income (expense), net $ 27 $ (40) Total reclassifications $ 27 $ (40) |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock-Based Compensation Plans The Company maintains the following plans for which awards were granted from or had shares outstanding in 2022: 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan (collectively referred to as the “Stock Plans”). Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $52.4 million and $163.5 million in stock-based compensation expense during the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, there was approximately $551.7 million of expected total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 3.1 years. In connection with the acquisition of Thrive, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the three months ended March 31, 2021, the Company accelerated 99,014 shares of previously unvested stock options and 27,479 shares of previously unvested restricted stock awards and restricted stock units and recorded $13.5 million of non-cash stock-based compensation for the accelerated awards. As further discussed in Note 16, the Company also recorded $86.2 million in stock-based compensation related to accelerated vesting of awards held by Thrive employees in connection with the acquisition. Stock Options A summary of stock option activity under the Stock Plans is as follows: Options Shares Weighted Weighted Aggregate (Aggregate intrinsic value in thousands) Outstanding, January 1, 2022 2,284,276 $ 34.65 5.5 Granted — — Exercised (485,653) 8.84 Forfeited (8,571) 86.02 Outstanding, March 31, 2022 1,790,052 $ 41.41 5.8 $ 63,737 Vested and expected to vest, March 31, 2022 1,790,052 $ 41.41 5.8 $ 63,737 Exercisable, March 31, 2022 1,509,645 $ 36.47 5.4 $ 58,202 ______________ (1) The total intrinsic value of options exercised during the three months ended March 31, 2022 and 2021 was $29.6 million and $126.0 million, respectively, determined as of the date of exercise. The Company received approximately $4.3 million and $8.8 million from stock option exercises during the three months ended March 31, 2022 and 2021, respectively. Restricted Stock and Restricted Stock Units The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day. A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2022 is as follows: Restricted stock and restricted stock units Shares Weighted Outstanding, January 1, 2022 4,320,910 $ 108.84 Granted 3,042,920 77.31 Released (1) (1,100,885) 100.61 Forfeited (235,095) 106.76 Outstanding, March 31, 2022 6,027,850 $ 94.35 ______________ (1) The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $110.8 million and $80.9 million during the three months ended March 31, 2022 and 2021, respectively. (2) The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2021 was $143.66. Performance Share Units The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones. In January 2022, the Company issued additional performance-based equity awards, which include a market condition in the form of a total shareholder return (“TSR”) modifier. At the end of the three-year performance period, the total units earned, if any, are adjusted by applying the modifier, ranging from 50% to 150%. The TSR modifier is based on stock price performance relative to a group of peer companies for the same three-year period. The fair value of the awards granted was calculated using a Monte Carlo simulation model, as the TSR modifier contains a market condition. A summary of performance share unit activity is as follows: Performance share units Shares (1) Weighted Outstanding, January 1, 2022 878,114 $ 107.18 Granted 711,629 92.31 Released (3) (292,134) 93.22 Forfeited (334,515) 94.30 Outstanding, March 31, 2022 963,094 $ 104.90 ______________ (1) The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2022 was 259,865. (2) The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2021 was $147.81. (3) The fair value of performance share units vested and converted to shares of the Company’s common stock was $27.2 million for the three months ended March 31, 2022. There were no performance share units vested and converted to shares of the Company’s common stock during the three months ended March 31, 2021. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Leases Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Three Months Ended March 31, (In thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 8,097 $ 5,558 Operating cash flows from finance leases 211 248 Finance cash flows from finance leases 1,548 1,203 Non-cash investing and financing activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) $ 4,259 $ 40,406 Right-of-use assets obtained in exchange for new finance lease liabilities 878 639 Weighted-average remaining lease term - operating leases (in years) 8.17 8.69 Weighted-average remaining lease term - finance leases (in years) 2.80 3.45 Weighted-average discount rate - operating leases 6.09 % 6.41 % Weighted-average discount rate - finance leases 5.32 % 5.66 % _____________ (1) For the three months ended March 31, 2021, this includes right-of-use assets acquired as part of the business combinations described in Note 16 of $39.6 million. As of March 31, 2022 and December 31, 2021, the Company’s right-of-use assets from operating leases are $170.4 million and $174.2 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of March 31, 2022, the Company has outstanding operating lease obligations of $200.3 million, of which $19.7 million is reported in operating lease liabilities, current portion and $180.6 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2021, the Company had outstanding operating lease obligations of $201.9 million, of which $19.7 million is reported in operating lease liabilities, current portion and $182.2 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of March 31, 2022 and December 31, 2021, the Company’s right-of-use assets from finance leases are $17.4 million and $18.2 million, respectively, which are reported in other long-term assets other current liabilities other long-term liabilities Legal Matters The Company records reserves and accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such reserves and accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices. As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation (the “DOS Rule Investigation”) discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity. The Company is currently responding to civil investigative demands and administrative subpoenas issued pursuant to the Health Insurance Portability and Accountability Act of 1996 by the United States Department of Justice (“DOJ”) concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations. The Company has been cooperating with these inquiries and has produced documents in response thereto. During the second quarter of 2021, as part of ongoing discussions between the DOJ and the Company regarding the DOS Rule Investigation, the DOJ presented an estimate of civil damages in the amount of $48.2 million relating to alleged non-compliance with the Medicare Date of Service billing regulations from 2007 to 2020. The civil damages estimate does not include potential treble damages, civil or criminal penalties or other remedies that the DOJ could seek against the Company. Based on the Company’s review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate, and range of potential exposure, the Company recorded an accrual of approximately $10 million as of March 31, 2022. As noted above, litigation outcomes are difficult to predict, and the estimation of probable losses requires an analysis of multiple possible outcomes that often depend on judgments about potential actions by third parties. Accordingly, the recorded accrual of approximately $10 million as of March 31, 2022 is based on several factors, considerations, and judgments, and the ultimate resolution of this matter could result in a loss in excess of the recorded accrual. On June 24, 2019, Niles Rosen M.D. filed a sealed ex parte qui tam lawsuit against the Company in the United States District Court for the Middle District of Florida, that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). Dr. Rosen seeks on behalf of the U.S. government and himself an award of civil penalties, treble damages and fees and costs. On February 25, 2020, the Company received a civil investigative demand by the DOJ related to the Company’s gift card program. The Company produced documents in response thereto. On March 25, 2021, the DOJ filed a notice of its election to decline intervention in the Qui Tam Suit. This election does not prevent Dr. Rosen from continuing the Qui Tam Suit. On April 12, 2021, Dr. Rosen filed an amended complaint against the Company, alleging violations of the Federal Anti-Kickback Statute and False Claims Act. The Company first learned of the Qui Tam Suit and the DOJ’s election to decline intervention in July 2021. The Company intends to vigorously defend itself against Dr. Rosen's claims and seek, among other things, the Company’s attorneys' fees and costs incurred in defending this action. Although the Company denies Dr. Rosen's allegations and believes that it has meritorious defenses to his False Claims Act claims, neither the outcome of the litigation nor can a reasonable estimate or an estimated range of loss associated with the litigation be determined at this time. |
WISCONSIN ECONOMIC DEVELOPMENT
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS | 3 Months Ended |
Mar. 31, 2022 | |
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Abstract] | |
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS | WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS During February 2015, the Company entered into an agreement with the Wisconsin Economic Development Corporation (“WEDC,” “Original WEDC Agreement”) to earn $9.0 million in refundable tax credits on the condition that the Company expends $26.3 million in capital investments and establishes and maintains 758 full-time positions over a seven-year period. During December 2021, the Company amended its agreement with the WEDC (“Amended WEDC Agreement”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement. The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC. Under the Original WEDC Agreement, the Company recorded the earned tax credits as job creation and capital investments occurred. The tax credits earned from capital investment are being recognized as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation were recognized as an offset to operational expenses through December 31, 2020. As of March 31, 2022, the Company has earned all $9.0 million of the refundable tax credits and has received payment of $9.0 million from the WEDC under the Original WEDC Agreement. Under the Amended WEDC Agreement, the Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. The credits recognized will be required to be repaid if the Company does not maintain minimum cumulative job requirements. As of March 31, 2022, the Company has earned $9.0 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $9.0 million as of March 31, 2022, of which $1.7 million is reported in prepaid expenses and other current assets and $7.3 million is reported in other long-term assets, reflecting when collection of the refundable tax credits is expected to occur. During the three months ended March 31, 2022, the Company recorded $1.0 million as a reduction to operational expenses for the credits earned for job creation. |
BUSINESS COMBINATIONS AND ASSET
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS | BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Business Combinations PreventionGenetics LLC On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a Clinical Laboratory Improvement Amendments (“CLIA”) certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2021, there were no material changes to the purchase price and purchase price allocation. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the intangible assets. Ashion Analytics, LLC On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of TGen. The Ashion Acquisition provided the Company a CLIA certified and CAP accredited sequencing lab based in Phoenix, Arizona. Ashion developed the GEMExTra® test, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2021, there were no changes to the purchase price allocation and the measurement period has closed. Thrive Earlier Detection Corporation On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive's early-stage multi-cancer early detection test with the Company’s scientific platform, clinical organization and commercial infrastructure will bring an accurate blood-based, multi-cancer detection test to patients faster. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, final purchase price allocation, and goodwill and intangible assets identified in the transaction. Asset Acquisitions PFS Genomics Inc. On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions. The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology. Refer to the Company’s 2021 10-K for detailed disclosures on the asset acquisition, including the fair value of the consideration transferred and purchase price allocation. TARDIS License Agreement On January 11, 2021, the Company entered into a worldwide exclusive license to the proprietary TARDIS technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company intends to develop and commercialize the TARDIS technology as a minimal residual disease test. The Company accounted for this transaction as an asset acquisition. Refer to the Company’s 2021 10-K for detailed disclosures on the asset acquisition, including the fair value of the consideration transferred and information related to contingent milestones. |
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS | BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Business Combinations PreventionGenetics LLC On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a Clinical Laboratory Improvement Amendments (“CLIA”) certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2021, there were no material changes to the purchase price and purchase price allocation. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the intangible assets. Ashion Analytics, LLC On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of TGen. The Ashion Acquisition provided the Company a CLIA certified and CAP accredited sequencing lab based in Phoenix, Arizona. Ashion developed the GEMExTra® test, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2021, there were no changes to the purchase price allocation and the measurement period has closed. Thrive Earlier Detection Corporation On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive's early-stage multi-cancer early detection test with the Company’s scientific platform, clinical organization and commercial infrastructure will bring an accurate blood-based, multi-cancer detection test to patients faster. Refer to the Company’s 2021 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, final purchase price allocation, and goodwill and intangible assets identified in the transaction. Asset Acquisitions PFS Genomics Inc. On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions. The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology. Refer to the Company’s 2021 10-K for detailed disclosures on the asset acquisition, including the fair value of the consideration transferred and purchase price allocation. TARDIS License Agreement On January 11, 2021, the Company entered into a worldwide exclusive license to the proprietary TARDIS technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company intends to develop and commercialize the TARDIS technology as a minimal residual disease test. The Company accounted for this transaction as an asset acquisition. Refer to the Company’s 2021 10-K for detailed disclosures on the asset acquisition, including the fair value of the consideration transferred and information related to contingent milestones. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
SEGMENT INFORMATION | SEGMENT INFORMATION Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the discrete financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results. The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location. Three Months Ended March 31, (In thousands) 2022 2021 United States $ 457,128 $ 376,021 Outside of United States 29,443 26,056 Total revenues $ 486,571 $ 402,077 Long-lived assets located in countries outside of the United States are not significant. |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company recorded an income tax benefit of $2.0 million and $242.8 million for the three months ended March 31, 2022 and 2021, respectively. The Company’s income tax benefit recorded during the three months ended March 31, 2022 is primarily related to the future limitations on and expiration of certain Federal and State deferred tax assets, offset by current foreign and state tax expense. A deferred tax liability of approximately $26.4 million was recorded as of March 31, 2022, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized. The Company had $23.1 million and $21.8 million of unrecognized tax benefits at March 31, 2022 and December 31, 2021, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months. As of March 31, 2022, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2002 through 2022, and to state income tax examinations for the tax years 2002 through 2022. No interest or penalties related to income taxes have been accrued or recognized as of March 31, 2022. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of ConsolidationThe accompanying condensed consolidated financial statements, which include the accounts of Exact Sciences Corporation and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “2021 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2021 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2021 Form 10-K. |
Use of Estimates | Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report and the 2021 Form 10-K. The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, marketable and non-marketable investments, software, and the carrying value of the goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. The pandemic and related precautionary measures began to materially disrupt the Company's operations in March 2020 and may continue to disrupt the business for an unknown period of time. As a result, the pandemic had an impact on the Company’s revenues and operating results. The ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity. |
Reclassifications | Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In October 2021, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805) |
Net Loss Per Share | Net Loss Per Share Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period: March 31, (In thousands) 2022 2021 Shares issuable in connection with acquisitions (1) 45 157 Shares issuable upon exercise of stock options 1,790 2,633 Shares issuable upon the release of restricted stock awards 6,991 4,467 Shares issuable upon the release of performance share units 963 846 Shares issuable upon conversion of convertible notes 20,309 20,309 30,098 28,412 ______________ |
REVENUE (Tables)
REVENUE (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of disaggregation of revenue | The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, (In thousands) 2022 2021 Screening Medicare Parts B & C $ 113,755 $ 101,559 Commercial 161,680 127,874 Other 31,087 10,895 Total Screening 306,522 240,328 Precision Oncology Medicare Parts B & C $ 52,565 $ 44,837 Commercial 46,062 46,812 International 29,443 26,056 Other 24,550 11,702 Total Precision Oncology 152,620 129,407 COVID-19 Testing $ 27,429 $ 32,342 Total $ 486,571 $ 402,077 |
MARKETABLE SECURITIES (Tables)
MARKETABLE SECURITIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
Schedule of cash and cash equivalents | The following table sets forth the Company’s cash, cash equivalents, restricted cash, and marketable securities at March 31, 2022 and December 31, 2021: (In thousands) March 31, 2022 December 31, 2021 Cash, cash equivalents, and restricted cash Cash and money market $ 135,320 $ 247,335 Cash equivalents 54,456 68,136 Restricted cash 297 297 Total cash, cash equivalents, and restricted cash 190,073 315,768 Marketable securities Available-for-sale debt securities $ 625,383 $ 711,669 Equity securities 1,821 3,336 Total marketable securities 627,204 715,005 Total cash and cash equivalents, restricted cash and marketable securities $ 817,277 $ 1,030,773 |
Schedule of restricted cash and cash equivalents | The following table sets forth the Company’s cash, cash equivalents, restricted cash, and marketable securities at March 31, 2022 and December 31, 2021: (In thousands) March 31, 2022 December 31, 2021 Cash, cash equivalents, and restricted cash Cash and money market $ 135,320 $ 247,335 Cash equivalents 54,456 68,136 Restricted cash 297 297 Total cash, cash equivalents, and restricted cash 190,073 315,768 Marketable securities Available-for-sale debt securities $ 625,383 $ 711,669 Equity securities 1,821 3,336 Total marketable securities 627,204 715,005 Total cash and cash equivalents, restricted cash and marketable securities $ 817,277 $ 1,030,773 |
Schedule of available-for-sale securities | Available-for-sale debt securities at March 31, 2022 consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Losses in Accumulated Estimated Fair Cash equivalents Commercial paper $ 51,979 $ — $ — $ 51,979 U.S. government agency securities 2,477 — — 2,477 Total cash equivalents 54,456 — — 54,456 Marketable securities Corporate bonds $ 229,768 $ — $ (1,952) $ 227,816 U.S. government agency securities 250,764 — (3,594) 247,170 Certificates of deposit 41,204 — (50) 41,154 Commercial paper 12,924 — (4) 12,920 Asset backed securities 97,156 — (833) 96,323 Total marketable securities 631,816 — (6,433) 625,383 Total available-for-sale securities $ 686,272 $ — $ (6,433) $ 679,839 ______________ (1) Gains and losses in accumulated other comprehensive income (loss) (“AOCI”) are reported before tax impact. Available-for-sale debt securities at December 31, 2021 consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Losses in Accumulated Estimated Fair Value Cash equivalents U.S. government agency securities $ 3,543 $ — $ — $ 3,543 Commercial paper 64,593 — — 64,593 Total cash equivalents 68,136 — — 68,136 Marketable securities U.S. government agency securities $ 250,793 $ — $ (873) $ 249,920 Asset backed securities 94,565 2 (107) 94,460 Commercial paper 6,996 — — 6,996 Certificates of deposit 47,147 2 (10) 47,139 Corporate bonds 313,634 13 (493) 313,154 Total marketable securities 713,135 17 (1,483) 711,669 Total available-for-sale securities $ 781,271 $ 17 $ (1,483) $ 779,805 ______________ (1) Gains and losses in AOCI are reported before tax impact. |
Schedule of contractual maturities of available-for-sale investments | The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2022: Due one year or less Due after one year through five years (In thousands) Cost Fair Value Cost Fair Value Cash equivalents Commercial paper $ 51,979 $ 51,979 $ — $ — U.S. government agency securities 2,477 2,477 — — Total cash equivalents 54,456 54,456 — — Marketable securities U.S. government agency securities $ 134,099 $ 132,683 $ 116,665 $ 114,487 Corporate bonds 114,973 114,482 114,795 113,334 Certificates of deposit 41,204 41,154 — — Asset backed securities — — 97,156 96,323 Commercial paper 12,924 12,920 — — Total marketable securities 303,200 301,239 328,616 324,144 Total $ 357,656 $ 355,695 $ 328,616 $ 324,144 |
Schedule of gross unrealized losses and fair values of investments in an unrealized loss position | The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than one year One year or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities Corporate bonds $ 216,816 $ (1,952) $ — $ — $ 216,816 $ (1,952) Certificates of deposit 41,154 (50) — — 41,154 (50) Asset backed securities 96,324 (833) — — 96,324 (833) U.S. government agency securities 247,170 (3,594) — — 247,170 (3,594) Commercial paper 3,989 (4) — — 3,989 (4) Total available-for-sale securities $ 605,453 $ (6,433) $ — $ — $ 605,453 $ (6,433) |
INVENTORY (Tables)
INVENTORY (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventory consisted of the following: (In thousands) March 31, 2022 December 31, 2021 Raw materials $ 55,402 $ 51,321 Semi-finished and finished goods 57,556 53,673 Total inventory $ 112,958 $ 104,994 |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Schedule of property, plant and equipment, net | The carrying value and estimated useful lives of property, plant and equipment are as follows: (In thousands) Estimated Useful Life March 31, 2022 December 31, 2021 Property, plant and equipment Land n/a $ 4,716 $ 4,716 Leasehold and building improvements (1) 166,286 147,083 Land improvements 15 years 5,206 5,206 Buildings 30 - 40 years 210,439 210,560 Computer equipment and computer software 3 years 117,393 109,119 Laboratory equipment 3 - 10 years 202,104 189,748 Furniture and fixtures 3 - 10 years 29,727 28,293 Assets under construction n/a 123,873 100,339 Property, plant and equipment, at cost 859,744 795,064 Accumulated depreciation (237,131) (214,816) Property, plant and equipment, net $ 622,613 $ 580,248 ______________ (1) Lesser of remaining lease term, building life, or estimated useful life. |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of net-book value and estimated remaining life and finite lived intangible assets | The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2022: (In thousands) Weighted Average Remaining Life (Years) Gross Carrying Amount Accumulated Amortization Net Balance at March 31, 2022 Finite-lived intangible assets Trade name 13.2 $ 104,700 $ (15,378) $ 89,322 Customer relationships 9.4 6,700 (1,712) 4,988 Patents 3.4 10,942 (7,110) 3,832 Acquired developed technology 8.4 918,171 (198,649) 719,522 Supply agreements 5.2 2,295 (202) 2,093 Total finite-lived intangible assets 1,042,808 (223,051) 819,757 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (223,051) $ 2,069,757 The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2021: (In thousands) Weighted Average Remaining Life (Years) Gross Carrying Amount Accumulated Amortization Net balance at December 31, 2021 Finite-lived intangible assets Trade name 13.4 $ 104,700 $ (13,554) $ 91,146 Customer relationships 9.6 6,700 (1,577) 5,123 Patents and licenses 3.6 10,942 (6,763) 4,179 Acquired developed technology 8.6 918,171 (176,402) 741,769 Supply agreements 5.4 2,295 (101) 2,194 Total finite-lived intangible assets 1,042,808 (198,397) 844,411 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (198,397) $ 2,094,411 |
Schedule of estimated future amortization expense, intangible assets | As of March 31, 2022, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows: (In thousands) 2022 (remaining nine months) $ 73,962 2023 98,611 2024 98,276 2025 97,228 2026 96,169 Thereafter 355,511 $ 819,757 |
Schedule of carrying amount of goodwill | The change in the carrying amount of goodwill for the periods ended March 31, 2022 and December 31, 2021 is as follows: (In thousands) Balance, January 1, 2021 $ 1,237,672 Thrive acquisition 948,105 Ashion acquisition 56,758 PreventionGenetics acquisition 92,637 Balance, December 31, 2021 2,335,172 Balance March 31, 2022 $ 2,335,172 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall | The following table presents the Company’s fair value measurements as of March 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at March 31, 2022 Quoted Prices Significant Other Significant Cash, cash equivalents, and restricted cash Cash and money market $ 135,320 $ 135,320 $ — $ — Commercial paper 51,979 — 51,979 — U.S. government agency securities 2,477 — 2,477 — Restricted cash 297 297 — — Marketable securities Corporate bonds $ 227,816 $ — $ 227,816 $ — Certificates of deposit 41,154 — 41,154 — Commercial paper 12,920 — 12,920 — U.S. government agency securities 247,170 — 247,170 — Asset backed securities 96,323 — 96,323 — Equity securities 1,821 1,821 — — Non-marketable securities $ 2,640 $ — $ — $ 2,640 Liabilities Contingent consideration $ (332,341) $ — $ — $ (332,341) Total $ 487,576 $ 137,438 $ 679,839 $ (329,701) The following table presents the Company’s fair value measurements as of December 31, 2021 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at December 31, 2021 Quoted Prices Significant Other Significant Cash and cash equivalents Cash and money market $ 247,335 $ 247,335 $ — $ — Commercial paper 64,593 — 64,593 — U.S. government agency securities 3,543 — 3,543 — Restricted cash 297 297 — — Marketable securities U.S. government agency securities $ 249,920 $ — $ 249,920 $ — Corporate bonds 313,154 — 313,154 — Asset backed securities 94,460 — 94,460 — Certificates of deposit 47,139 — 47,139 — Commercial paper 6,996 — 6,996 — Equity securities 3,336 3,336 — — Non-marketable securities $ 3,090 $ — $ — $ 3,090 Liabilities Contingent consideration $ (359,021) $ — $ — $ (359,021) Total $ 674,842 $ 250,968 $ 779,805 $ (355,931) |
Schedule of fair value of contingent consideration | The following table provides a reconciliation of the beginning and ending balances of contingent consideration: (In thousands) Contingent Consideration Beginning balance, January 1, 2022 $ 359,021 Changes in fair value (26,680) Ending balance, March 31, 2022 $ 332,341 |
CONVERTIBLE NOTES (Tables)
CONVERTIBLE NOTES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
CONVERTIBLE NOTES [Abstract] | |
Schedule of convertible note obligations included in the condensed consolidated balance sheets | Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2022: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,074) $ 1,131,926 $ 1,032,125 2 2027 Convertible notes - 0.375% 747,500 (11,137) 736,363 712,315 2 2025 Convertible notes - 1.000% 315,005 (1,614) 313,391 377,833 2 Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2021: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,826) $ 1,131,174 $ 1,139,650 2 2027 Convertible notes - 0.375% 747,500 (11,691) 735,809 771,794 2 2025 Convertible notes - 1.000% 315,005 (1,756) 313,249 415,473 2 ______________ |
Schedule of allocation of transaction costs related to convertible debt | The following table summarizes the original issuance costs at the time of issuance for each set of Notes: (In thousands) January 2025 Notes $ 10,284 June 2025 Notes 7,362 2027 Notes 14,285 2028 Notes 24,453 |
Schedule of interest expense | Interest expense includes the following: Three Months Ended March 31, (In thousands) 2022 2021 Debt issuance costs amortization $ 1,412 $ 1,413 Debt discount amortization 36 36 Coupon interest expense 2,567 2,567 Total interest expense on convertible notes 4,015 4,016 Other interest expense 463 600 Total interest expense $ 4,478 $ 4,616 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) | The amount recognized in AOCI for the three months ended March 31, 2022 were as follows: (In thousands) Foreign Currency Translation Adjustments Unrealized Accumulated Balance at December 31, 2021 $ 23 $ (1,466) $ (1,443) Other comprehensive loss before reclassifications (237) (4,994) (5,231) Amounts reclassified from accumulated other comprehensive loss — 27 27 Net current period change in accumulated other comprehensive loss (237) (4,967) (5,204) Balance at March 31, 2022 $ (214) $ (6,433) $ (6,647) ______________ (1) There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022. The amounts recognized in AOCI for the three months ended March 31, 2021 were as follows: (In thousands) Unrealized Accumulated Balance at December 31, 2020 $ 526 $ 526 Other comprehensive loss before reclassifications (292) (292) Amounts reclassified from accumulated other comprehensive income (40) (40) Net current period change in accumulated other comprehensive income, before tax (332) (332) Income tax benefit related to items of other comprehensive income 170 170 Balance at March 31, 2021 $ 364 $ 364 |
Schedule of amounts reclassified from accumulated other comprehensive income (loss) | Amounts reclassified from AOCI for the three months ended March 31, 2022 and 2021 were as follows: Affected Line Item in the Three Months Ended March 31, Details about AOCI Components (In thousands) 2022 2021 Change in value of available-for-sale investments Sales and maturities of available-for-sale investments Investment income (expense), net $ 27 $ (40) Total reclassifications $ 27 $ (40) |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Summary of stock option activity under the Stock Plans | A summary of stock option activity under the Stock Plans is as follows: Options Shares Weighted Weighted Aggregate (Aggregate intrinsic value in thousands) Outstanding, January 1, 2022 2,284,276 $ 34.65 5.5 Granted — — Exercised (485,653) 8.84 Forfeited (8,571) 86.02 Outstanding, March 31, 2022 1,790,052 $ 41.41 5.8 $ 63,737 Vested and expected to vest, March 31, 2022 1,790,052 $ 41.41 5.8 $ 63,737 Exercisable, March 31, 2022 1,509,645 $ 36.47 5.4 $ 58,202 ______________ (1) The total intrinsic value of options exercised during the three months ended March 31, 2022 and 2021 was $29.6 million and $126.0 million, respectively, determined as of the date of exercise. |
Summary of restricted stock and restricted stock unit activity under the Stock Plans | A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2022 is as follows: Restricted stock and restricted stock units Shares Weighted Outstanding, January 1, 2022 4,320,910 $ 108.84 Granted 3,042,920 77.31 Released (1) (1,100,885) 100.61 Forfeited (235,095) 106.76 Outstanding, March 31, 2022 6,027,850 $ 94.35 ______________ (1) The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $110.8 million and $80.9 million during the three months ended March 31, 2022 and 2021, respectively. (2) The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2021 was $143.66. |
Share-based payment arrangement, performance shares, activity | A summary of performance share unit activity is as follows: Performance share units Shares (1) Weighted Outstanding, January 1, 2022 878,114 $ 107.18 Granted 711,629 92.31 Released (3) (292,134) 93.22 Forfeited (334,515) 94.30 Outstanding, March 31, 2022 963,094 $ 104.90 ______________ (1) The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2022 was 259,865. (2) The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2021 was $147.81. |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Supplemental disclosure of cash flow information related to our operating leases | Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Three Months Ended March 31, (In thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 8,097 $ 5,558 Operating cash flows from finance leases 211 248 Finance cash flows from finance leases 1,548 1,203 Non-cash investing and financing activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) $ 4,259 $ 40,406 Right-of-use assets obtained in exchange for new finance lease liabilities 878 639 Weighted-average remaining lease term - operating leases (in years) 8.17 8.69 Weighted-average remaining lease term - finance leases (in years) 2.80 3.45 Weighted-average discount rate - operating leases 6.09 % 6.41 % Weighted-average discount rate - finance leases 5.32 % 5.66 % _____________ (1) For the three months ended March 31, 2021, this includes right-of-use assets acquired as part of the business combinations described in Note 16 of $39.6 million. |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
Revenue from external customers by geographic areas | The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location. Three Months Ended March 31, (In thousands) 2022 2021 United States $ 457,128 $ 376,021 Outside of United States 29,443 26,056 Total revenues $ 486,571 $ 402,077 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 30,098 | 28,412 |
Shares issuable in connection with acquisitions | ||
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 45 | 157 |
Shares issuable upon exercise of stock options | ||
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 1,790 | 2,633 |
Shares issuable upon the release of restricted stock awards | ||
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 6,991 | 4,467 |
Shares issuable upon the release of performance share units | ||
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 963 | 846 |
Shares issuable upon conversion of convertible notes | ||
Common shares not included in the computation of diluted net loss per share | ||
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | 20,309 | 20,309 |
REVENUE - Schedule of Disaggreg
REVENUE - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | $ 486,571 | $ 402,077 |
Screening | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 306,522 | 240,328 |
Screening | Medicare Parts B & C | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 113,755 | 101,559 |
Screening | Commercial | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 161,680 | 127,874 |
Screening | Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 31,087 | 10,895 |
Precision Oncology | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 152,620 | 129,407 |
Precision Oncology | Medicare Parts B & C | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 52,565 | 44,837 |
Precision Oncology | Commercial | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 46,062 | 46,812 |
Precision Oncology | Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 24,550 | 11,702 |
Precision Oncology | International | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | 29,443 | 26,056 |
COVID-19 Testing | ||
Disaggregation of Revenue [Line Items] | ||
Revenue recognized | $ 27,429 | $ 32,342 |
REVENUE - Narrative (Details)
REVENUE - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | |||
Deferred revenue | $ 1.3 | $ 1 | |
Deferred revenue, revenue recognized during period | 0.3 | $ 14 | |
COVID-19 | |||
Disaggregation of Revenue [Line Items] | |||
Deferred revenue, revenue recognized during period | 13.8 | ||
Variable consideration | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized from changes in transaction prices | $ 4.2 | $ 1.7 |
MARKETABLE SECURITIES - Schedul
MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Marketable Securities [Line Items] | ||||
Cash and money market | $ 135,320 | $ 247,335 | ||
Cash equivalents | 54,456 | 68,136 | ||
Restricted cash | 297 | 297 | $ 284 | |
Total cash, cash equivalents and restricted cash | 190,073 | 315,768 | $ 1,104,100 | $ 1,491,594 |
Available-for-sale debt securities | 679,839 | 779,805 | ||
Equity securities | 1,821 | 3,336 | ||
Total marketable securities | 627,204 | 715,005 | ||
Total cash and cash equivalents, restricted cash and marketable securities | 817,277 | 1,030,773 | ||
Marketable securities | ||||
Marketable Securities [Line Items] | ||||
Available-for-sale debt securities | $ 625,383 | $ 711,669 |
MARKETABLE SECURITIES - Sched_2
MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Available-for-sale securities | ||
Amortized Cost | $ 686,272 | $ 781,271 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 17 |
Losses in Accumulated Other Comprehensive Income (Loss) | (6,433) | (1,483) |
Estimated Fair Value | 679,839 | 779,805 |
Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 54,456 | 68,136 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 54,456 | 68,136 |
Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 631,816 | 713,135 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 17 |
Losses in Accumulated Other Comprehensive Income (Loss) | (6,433) | (1,483) |
Estimated Fair Value | 625,383 | 711,669 |
Commercial paper | Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 51,979 | 64,593 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 51,979 | 64,593 |
U.S. government agency securities | Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 2,477 | 3,543 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 2,477 | 3,543 |
U.S. government agency securities | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 250,764 | 250,793 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | (3,594) | (873) |
Estimated Fair Value | 247,170 | 249,920 |
Corporate bonds | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 229,768 | 313,634 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 13 |
Losses in Accumulated Other Comprehensive Income (Loss) | (1,952) | (493) |
Estimated Fair Value | 227,816 | 313,154 |
Certificates of deposit | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 41,204 | 47,147 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 2 |
Losses in Accumulated Other Comprehensive Income (Loss) | (50) | (10) |
Estimated Fair Value | 41,154 | 47,139 |
Commercial paper, not included with cash equivalents | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 12,924 | 6,996 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | (4) | 0 |
Estimated Fair Value | 12,920 | 6,996 |
Asset backed securities | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 97,156 | 94,565 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 2 |
Losses in Accumulated Other Comprehensive Income (Loss) | (833) | (107) |
Estimated Fair Value | $ 96,323 | $ 94,460 |
MARKETABLE SECURITIES - Sched_3
MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) $ in Thousands | Mar. 31, 2022USD ($) |
Available-for-sale securities | |
Due in one year or less, Cost | $ 357,656 |
Due in one year or less, Fair Value | 355,695 |
Due after one year through five years, Cost | 328,616 |
Due after one year through five years, Fair Value | 324,144 |
Cash equivalents | |
Available-for-sale securities | |
Due in one year or less, Cost | 54,456 |
Due in one year or less, Fair Value | 54,456 |
Due after one year through five years, Cost | 0 |
Due after one year through five years, Fair Value | 0 |
Cash equivalents | Commercial paper | |
Available-for-sale securities | |
Due in one year or less, Cost | 51,979 |
Due in one year or less, Fair Value | 51,979 |
Due after one year through five years, Cost | 0 |
Due after one year through five years, Fair Value | 0 |
Cash equivalents | U.S. government agency securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 2,477 |
Due in one year or less, Fair Value | 2,477 |
Due after one year through five years, Cost | 0 |
Due after one year through five years, Fair Value | 0 |
Marketable securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 303,200 |
Due in one year or less, Fair Value | 301,239 |
Due after one year through five years, Cost | 328,616 |
Due after one year through five years, Fair Value | 324,144 |
Marketable securities | Commercial paper | |
Available-for-sale securities | |
Due in one year or less, Cost | 12,924 |
Due in one year or less, Fair Value | 12,920 |
Due after one year through five years, Cost | 0 |
Due after one year through five years, Fair Value | 0 |
Marketable securities | U.S. government agency securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 134,099 |
Due in one year or less, Fair Value | 132,683 |
Due after one year through five years, Cost | 116,665 |
Due after one year through five years, Fair Value | 114,487 |
Marketable securities | Corporate bonds | |
Available-for-sale securities | |
Due in one year or less, Cost | 114,973 |
Due in one year or less, Fair Value | 114,482 |
Due after one year through five years, Cost | 114,795 |
Due after one year through five years, Fair Value | 113,334 |
Marketable securities | Certificates of deposit | |
Available-for-sale securities | |
Due in one year or less, Cost | 41,204 |
Due in one year or less, Fair Value | 41,154 |
Due after one year through five years, Cost | 0 |
Due after one year through five years, Fair Value | 0 |
Marketable securities | Asset backed securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 0 |
Due in one year or less, Fair Value | 0 |
Due after one year through five years, Cost | 97,156 |
Due after one year through five years, Fair Value | $ 96,323 |
MARKETABLE SECURITIES - Sched_4
MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) $ in Thousands | Mar. 31, 2022USD ($) |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | $ 605,453 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (6,433) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 605,453 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (6,433) |
Corporate bonds | Marketable securities | |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 216,816 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (1,952) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 216,816 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (1,952) |
Certificates of deposit | Marketable securities | |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 41,154 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (50) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 41,154 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (50) |
Asset backed securities | Marketable securities | |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 96,324 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (833) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 96,324 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (833) |
U.S. government agency securities | Marketable securities | |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 247,170 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (3,594) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 247,170 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (3,594) |
Commercial paper | Marketable securities | |
Marketable Securities [Line Items] | |
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 3,989 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (4) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 3,989 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | $ (4) |
INVENTORY (Details)
INVENTORY (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 55,402 | $ 51,321 |
Semi-finished and finished goods | 57,556 | 53,673 |
Total inventory | $ 112,958 | $ 104,994 |
PROPERTY, PLANT AND EQUIPMENT -
PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 859,744 | $ 795,064 |
Accumulated depreciation | (237,131) | (214,816) |
Property, plant and equipment, net | 622,613 | 580,248 |
Land | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | 4,716 | 4,716 |
Leasehold and building improvements | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 166,286 | 147,083 |
Land improvements | ||
Property, plant and equipment | ||
Estimated Useful Life | 15 years | |
Property, plant and equipment, at cost | $ 5,206 | 5,206 |
Buildings | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 210,439 | 210,560 |
Computer equipment and computer software | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Property, plant and equipment, at cost | $ 117,393 | 109,119 |
Laboratory equipment | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | 202,104 | 189,748 |
Furniture and fixtures | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | 29,727 | 28,293 |
Assets under construction | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 123,873 | $ 100,339 |
Minimum | Buildings | ||
Property, plant and equipment | ||
Estimated Useful Life | 30 years | |
Minimum | Laboratory equipment | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Minimum | Furniture and fixtures | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Maximum | Buildings | ||
Property, plant and equipment | ||
Estimated Useful Life | 40 years | |
Maximum | Laboratory equipment | ||
Property, plant and equipment | ||
Estimated Useful Life | 10 years | |
Maximum | Furniture and fixtures | ||
Property, plant and equipment | ||
Estimated Useful Life | 10 years |
PROPERTY, PLANT AND EQUIPMENT_2
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Property, plant and equipment | ||
Depreciation | $ 23 | $ 20.5 |
Assets under construction | 123.9 | |
Buildings | ||
Property, plant and equipment | ||
Assets under construction | 69.1 | |
Laboratory equipment | ||
Property, plant and equipment | ||
Assets under construction | 26.4 | |
Leasehold and building improvements | ||
Property, plant and equipment | ||
Assets under construction | 16.2 | |
Computer software | ||
Property, plant and equipment | ||
Assets under construction | 11.5 | |
Land improvements | ||
Property, plant and equipment | ||
Assets under construction | $ 0.7 |
INTANGIBLE ASSETS AND GOODWIL_2
INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross | $ 1,042,808 | $ 1,042,808 |
Less: Accumulated amortization | (223,051) | (198,397) |
Intangibles, net | 819,757 | 844,411 |
In-process research and development | 1,250,000 | 1,250,000 |
Finite-lived and indefinite-lived intangible assets, gross | 2,292,808 | 2,292,808 |
Finite-lived and indefinite-lived intangible assets, net | $ 2,069,757 | $ 2,094,411 |
Trade name | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 13 years 2 months 12 days | 13 years 4 months 24 days |
Finite-lived intangible assets, gross | $ 104,700 | $ 104,700 |
Less: Accumulated amortization | (15,378) | (13,554) |
Intangibles, net | $ 89,322 | $ 91,146 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 9 years 4 months 24 days | 9 years 7 months 6 days |
Finite-lived intangible assets, gross | $ 6,700 | $ 6,700 |
Less: Accumulated amortization | (1,712) | (1,577) |
Intangibles, net | $ 4,988 | $ 5,123 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 3 years 4 months 24 days | 3 years 7 months 6 days |
Finite-lived intangible assets, gross | $ 10,942 | $ 10,942 |
Less: Accumulated amortization | (7,110) | (6,763) |
Intangibles, net | $ 3,832 | $ 4,179 |
Acquired developed technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 8 years 4 months 24 days | 8 years 7 months 6 days |
Finite-lived intangible assets, gross | $ 918,171 | $ 918,171 |
Less: Accumulated amortization | (198,649) | (176,402) |
Intangibles, net | $ 719,522 | $ 741,769 |
Supply agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 5 years 2 months 12 days | 5 years 4 months 24 days |
Finite-lived intangible assets, gross | $ 2,295 | $ 2,295 |
Less: Accumulated amortization | (202) | (101) |
Intangibles, net | $ 2,093 | $ 2,194 |
INTANGIBLE ASSETS AND GOODWIL_3
INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2022 (remaining nine months) | $ 73,962 | |
2023 | 98,611 | |
2024 | 98,276 | |
2025 | 97,228 | |
2026 | 96,169 | |
Thereafter | 355,511 | |
Intangibles, net | $ 819,757 | $ 844,411 |
INTANGIBLE ASSETS AND GOODWIL_4
INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Recognized Goodwill | |
Beginning balance | $ 1,237,672 |
Ending balance | 2,335,172 |
Thrive | |
Recognized Goodwill | |
Goodwill acquired during the period | 948,105 |
Ashion Analytics | |
Recognized Goodwill | |
Goodwill acquired during the period | 56,758 |
PreventionGenetics LLC | |
Recognized Goodwill | |
Goodwill acquired during the period | $ 92,637 |
INTANGIBLE ASSETS AND GOODWIL_5
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Impairment losses | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Sched
FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Fair value measurements | ||
Estimated Fair Value | $ 679,839 | $ 779,805 |
Equity securities | 1,821 | 3,336 |
Fair Value, Recurring | ||
Fair value measurements | ||
Restricted cash | 297 | 297 |
Equity securities | 1,821 | 3,336 |
Non-marketable securities | 2,640 | 3,090 |
Contingent consideration | (332,341) | (359,021) |
Total | 487,576 | 674,842 |
Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 227,816 | 313,154 |
Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 41,154 | 47,139 |
Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 12,920 | 6,996 |
Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 247,170 | 249,920 |
Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 96,323 | 94,460 |
Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 135,320 | 247,335 |
Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 51,979 | 64,593 |
Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 2,477 | 3,543 |
Level 1 | Fair Value, Recurring | ||
Fair value measurements | ||
Restricted cash | 297 | 297 |
Equity securities | 1,821 | 3,336 |
Non-marketable securities | 0 | 0 |
Contingent consideration | 0 | 0 |
Total | 137,438 | 250,968 |
Level 1 | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 1 | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 1 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 1 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 1 | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 1 | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 135,320 | 247,335 |
Level 1 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 0 | 0 |
Level 1 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 0 | 0 |
Level 2 | Fair Value, Recurring | ||
Fair value measurements | ||
Restricted cash | 0 | 0 |
Equity securities | 0 | 0 |
Non-marketable securities | 0 | 0 |
Contingent consideration | 0 | 0 |
Total | 679,839 | 779,805 |
Level 2 | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 227,816 | 313,154 |
Level 2 | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 41,154 | 47,139 |
Level 2 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 12,920 | 6,996 |
Level 2 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 247,170 | 249,920 |
Level 2 | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 96,323 | 94,460 |
Level 2 | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 0 | 0 |
Level 2 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 51,979 | 64,593 |
Level 2 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 2,477 | 3,543 |
Level 3 | Fair Value, Recurring | ||
Fair value measurements | ||
Restricted cash | 0 | 0 |
Equity securities | 0 | 0 |
Non-marketable securities | 2,640 | 3,090 |
Contingent consideration | (332,341) | (359,021) |
Total | (329,701) | (355,931) |
Level 3 | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 3 | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 3 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 3 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 3 | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Level 3 | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 0 | 0 |
Level 3 | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | 0 | 0 |
Level 3 | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Cash, cash equivalents, and restricted cash | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Narra
FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022USD ($) | Dec. 31, 2021USD ($) | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Contingent consideration | $ 332,341 | $ 359,021 |
Venture Capital Investment Fund | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Investment owned, at fair value | 2,700 | $ 1,500 |
Committed capital | 17,500 | |
Committed capital callable | $ 14,800 | |
Product Development and Other Milestone-based Payments | Weighted Average | Measurement Input, Probability of Success | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Contingent consideration liability, measurement input | 0.91 | 0.91 |
Product Development and Other Milestone-based Payments | Weighted Average | Measurement Input, Present-value Factor | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Contingent consideration liability, measurement input | 0.045 | 0.023 |
Foreign Exchange Forward | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Derivative, notional amount | $ 48,900 | $ 46,700 |
Level 3 | Fair Value, Nonrecurring | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Investment owned, at fair value | 25,900 | 25,300 |
Thrive and Ashion | Fair Value | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Contingent consideration | 331,100 | 357,800 |
Biomatrica, Inc | Revenue and Other Performance-based Payments | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Contingent consideration | $ 1,200 | $ 1,200 |
FAIR VALUE MEASUREMENTS - Fair
FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | ||
Beginning balance | $ 359,021 | |
Changes in fair value | (26,680) | $ 2,879 |
Ending balance | $ 332,341 |
LONG-TERM DEBT - Narrative (Det
LONG-TERM DEBT - Narrative (Details) - Revolving Loan Agreement - Line of Credit - USD ($) | 1 Months Ended | 3 Months Ended | |
Nov. 30, 2021 | Dec. 31, 2021 | Mar. 31, 2022 | |
Revolving Loan Agreement | |||
Long-term debt | |||
Maximum borrowing capacity | $ 150,000,000 | ||
Minimum market value covenant | 150,000,000 | ||
Maximum outstanding cash advances threshold | $ 20,000,000 | ||
Remaining borrowing capacity | $ 147,100,000 | $ 147,100,000 | |
Revolving Loan Agreement | Daily Bloomberg Short-Term Bank Yield Index Rate | |||
Long-term debt | |||
Variable rate | 0.60% | ||
City Letter of Credit | |||
Long-term debt | |||
Proceeds from lines of credit | $ 2,900,000 |
CONVERTIBLE NOTES - Schedule of
CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
2028 Notes | ||
Long-term debt | ||
Coupon interest rate | 0.375% | 0.375% |
Principal Amount | $ 1,150,000 | $ 1,150,000 |
Unamortized Debt Discount and Issuance Costs | (18,074) | (18,826) |
Net Carrying Amount | 1,131,926 | 1,131,174 |
2028 Notes | Level 2 | Fair Value | ||
Long-term debt | ||
Convertible notes, fair value | $ 1,032,125 | $ 1,139,650 |
2027 Notes | ||
Long-term debt | ||
Coupon interest rate | 0.375% | 0.375% |
Principal Amount | $ 747,500 | $ 747,500 |
Unamortized Debt Discount and Issuance Costs | (11,137) | (11,691) |
Net Carrying Amount | 736,363 | 735,809 |
2027 Notes | Level 2 | Fair Value | ||
Long-term debt | ||
Convertible notes, fair value | $ 712,315 | $ 771,794 |
2025 notes | ||
Long-term debt | ||
Coupon interest rate | 1.00% | 1.00% |
Principal Amount | $ 315,005 | $ 315,005 |
Unamortized Debt Discount and Issuance Costs | (1,614) | (1,756) |
Net Carrying Amount | 313,391 | 313,249 |
2025 notes | Level 2 | Fair Value | ||
Long-term debt | ||
Convertible notes, fair value | $ 377,833 | $ 415,473 |
CONVERTIBLE NOTES - Narrative (
CONVERTIBLE NOTES - Narrative (Details) shares in Millions | 3 Months Ended | |
Mar. 31, 2022shares$ / shares | Mar. 31, 2021 | |
Long-term debt | ||
Repurchase price, as percentage of principal amount, if company undergoes change of control | 100 | |
Market price (in dollars per share) | $ 69.92 | |
2025 notes | ||
Long-term debt | ||
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares) | 13.26 | |
Conversion price (in dollars per share) | $ 75.43 | |
Convertible debt, if-converted (in shares) | shares | 4.2 | |
Effective interest rate (as a percent) | 1.18% | 1.18% |
Interest expense amortization term | 2 years 9 months 18 days | |
2027 Notes | ||
Long-term debt | ||
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares) | 8.96 | |
Conversion price (in dollars per share) | $ 111.66 | |
Convertible debt, if-converted (in shares) | shares | 6.7 | |
Effective interest rate (as a percent) | 0.67% | 0.67% |
Interest expense amortization term | 4 years 11 months 15 days | |
2028 Notes | ||
Long-term debt | ||
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares) | 8.21 | |
Conversion price (in dollars per share) | $ 121.84 | |
Convertible debt, if-converted (in shares) | shares | 9.4 | |
Effective interest rate (as a percent) | 0.64% | 0.64% |
Interest expense amortization term | 5 years 11 months 1 day |
CONVERTIBLE NOTES - Schedule _2
CONVERTIBLE NOTES - Schedule of Transaction Costs (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($) | |
January 2025 Notes | |
Long-term debt | |
Total transaction costs | $ 10,284 |
June 2025 Notes | |
Long-term debt | |
Total transaction costs | 7,362 |
2027 Notes | |
Long-term debt | |
Total transaction costs | 14,285 |
2028 Notes | |
Long-term debt | |
Total transaction costs | $ 24,453 |
CONVERTIBLE NOTES - Summary of
CONVERTIBLE NOTES - Summary of Interest Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Debt Disclosure [Abstract] | ||
Debt issuance costs amortization | $ 1,412 | $ 1,413 |
Debt discount amortization | 36 | 36 |
Coupon interest expense | 2,567 | 2,567 |
Total interest expense on convertible notes | 4,015 | 4,016 |
Other interest expense | 463 | 600 |
Total interest expense | $ 4,478 | $ 4,616 |
LICENSE AND COLLABORATION AGR_2
LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2022USD ($) | Mar. 31, 2021USD ($) | Sep. 30, 2020USD ($)installment | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Research and development expense | $ 102,248 | $ 115,567 | |
Licensing Agreements | Mayo | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
License agreement fees commitment | $ 6,300 | ||
Number of installments | installment | 5 | ||
Period patent remains in effect | 5 years | ||
Licensing Agreements | Mayo | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Research and development expense | $ 1,400 | $ 1,200 |
LICENSE AND COLLABORATION AGR_3
LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) - Thrive - Licensing Agreements $ in Millions | Jan. 05, 2021USD ($) |
Sales Milestone Range One | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Payments contingent on milestones | $ 10 |
Collaborative arrangement sales milestone amount | 500 |
Sales Milestone Range Two | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Payments contingent on milestones | 15 |
Collaborative arrangement sales milestone amount | 1,000 |
Sales Milestone Range Three | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Payments contingent on milestones | 20 |
Collaborative arrangement sales milestone amount | $ 1,500 |
PFIZER PROMOTION AGREEMENT (Det
PFIZER PROMOTION AGREEMENT (Details) - Cologuard promotion agreement - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Nov. 30, 2021 | |
Pfizer Inc | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Contract termination fee | $ 35.9 | ||
Pfizer Inc | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Service fee based on incremental gross profits over specified baselines and royalties | $ 2.5 | $ 22.7 | |
Charges for promotion, sales and marketing | $ 38.4 | $ 26.6 |
STOCKHOLDERS' EQUITY - Narrativ
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) shares in Millions, $ in Millions | Dec. 31, 2021 | Apr. 14, 2021 | Jan. 11, 2021 | Jan. 05, 2021 | Apr. 26, 2022 |
Subsequent Event | |||||
Subsidiary or Equity Method Investee [Line Items] | |||||
Issuance of common stock to fund the Company's 401(k) match (in shares) | 0.4 | ||||
TARDIS Technology | |||||
Subsidiary or Equity Method Investee [Line Items] | |||||
Payments to acquire productive assets (in shares) | 0.2 | ||||
Stock issued to acquire productive assets, value | $ 27.3 | ||||
PreventionGenetics LLC | |||||
Subsidiary or Equity Method Investee [Line Items] | |||||
Business acquisition, equity interest issued or issuable (in shares) | 1.1 | ||||
Fair value of stock issued in acquisition | $ 84.2 | ||||
Ashion Analytics | |||||
Subsidiary or Equity Method Investee [Line Items] | |||||
Business acquisition, equity interest issued or issuable (in shares) | 0.1 | ||||
Fair value of stock issued in acquisition | $ 16.2 | ||||
Thrive | |||||
Subsidiary or Equity Method Investee [Line Items] | |||||
Business acquisition, equity interest issued or issuable (in shares) | 9.3 | ||||
Fair value of stock issued in acquisition | $ 1,190 |
STOCKHOLDERS' EQUITY - Schedule
STOCKHOLDERS' EQUITY - Schedule of OCI (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | $ 3,387,636 | $ 2,235,552 |
Other comprehensive loss before reclassifications | (5,231) | (292) |
Amounts reclassified from accumulated other comprehensive income | 27 | (40) |
Net current period change in accumulated other comprehensive income, before tax | (5,204) | (332) |
Income tax benefit related to items of other comprehensive income | 170 | |
Ending balance | 3,258,211 | 3,648,995 |
Foreign Currency Translation Adjustments | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | 23 | |
Other comprehensive loss before reclassifications | (237) | |
Amounts reclassified from accumulated other comprehensive income | 0 | |
Net current period change in accumulated other comprehensive income, before tax | (237) | |
Ending balance | (214) | |
Unrealized Gain (Loss) on Marketable Securities | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (1,466) | 526 |
Other comprehensive loss before reclassifications | (4,994) | (292) |
Amounts reclassified from accumulated other comprehensive income | 27 | (40) |
Net current period change in accumulated other comprehensive income, before tax | (4,967) | (332) |
Income tax benefit related to items of other comprehensive income | 170 | |
Ending balance | (6,433) | 364 |
Accumulated Other Comprehensive Income (Loss) | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (1,443) | 526 |
Ending balance | $ (6,647) | $ 364 |
STOCKHOLDERS' EQUITY - Schedu_2
STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) - Reclassification Out Of Accumulated Other Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Changes in Accumulated Other Comprehensive Income (Loss) | ||
Total reclassifications | $ 27 | $ (40) |
Unrealized Gain (Loss) on Marketable Securities | ||
Changes in Accumulated Other Comprehensive Income (Loss) | ||
Investment income (expense), net | $ 27 | $ (40) |
STOCK-BASED COMPENSATION - Narr
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands | Jan. 05, 2021 | Jan. 31, 2022 | Mar. 31, 2022 | Mar. 31, 2021 |
Stock-based compensation | ||||
Stock-based compensation expense | $ 52,400 | $ 163,500 | ||
Noncash stock-based compensation expense | 52,441 | 77,292 | ||
Proceeds from stock options exercised | 4,300 | 8,800 | ||
Stock Plans | ||||
Stock-based compensation | ||||
Unrecognized compensation cost | $ 551,700 | |||
Weighted average period for recognition of cost | 3 years 1 month 6 days | |||
Thrive | ||||
Stock-based compensation | ||||
Noncash stock-based compensation expense | $ 13,500 | |||
Thrive | General and Administrative Expense | ||||
Stock-based compensation | ||||
Accelerated vesting compensation expense | $ 86,200 | |||
Stock Option | Thrive | ||||
Stock-based compensation | ||||
Accelerated vesting (in shares) | 99,014 | |||
Restricted Stock Units | Thrive | ||||
Stock-based compensation | ||||
Accelerated vesting (in shares) | 27,479 | |||
Performance Share Units | ||||
Stock-based compensation | ||||
Award performance period | 3 years | |||
Performance Share Units | Minimum | ||||
Stock-based compensation | ||||
Award multiplier percentage | 50.00% | |||
Performance Share Units | Maximum | ||||
Stock-based compensation | ||||
Award multiplier percentage | 150.00% | |||
Employee stock | Employee Stock Purchase Plan2010 | ||||
Stock-based compensation | ||||
Purchase of employee stock purchase plan shares (in shares) | 0 | 0 |
STOCK-BASED COMPENSATION - Fair
STOCK-BASED COMPENSATION - Fair Value and Activity (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Restricted Shares and RSUs | |||
Restricted Shares, RSUs, and Performance Share Units | |||
Outstanding at the beginning of the period (in shares) | 4,320,910 | ||
Granted (in shares) | 3,042,920 | ||
Released (in shares) | (1,100,885) | ||
Forfeited (in shares) | (235,095) | ||
Outstanding at the end of the period (in shares) | 6,027,850 | 4,320,910 | |
Weighted Average Grant Date Fair Value | |||
Outstanding at the beginning of the period (in dollars per share) | $ 108.84 | ||
Granted (in dollars per share) | 77.31 | ||
Released (in dollars per share) | 100.61 | ||
Forfeited (in dollars per share) | 106.76 | ||
Outstanding at the end of the period (in dollars per share) | $ 94.35 | $ 108.84 | |
Fair value of equity instruments other than options vested in period | $ 110,800,000 | $ 80,900,000 | |
Restricted Stock Units | |||
Weighted Average Grant Date Fair Value | |||
Granted (in dollars per share) | $ 143.66 | ||
Performance Share Units | |||
Restricted Shares, RSUs, and Performance Share Units | |||
Outstanding at the beginning of the period (in shares) | 878,114 | ||
Granted (in shares) | 711,629 | ||
Released (in shares) | (292,134) | ||
Forfeited (in shares) | (334,515) | ||
Outstanding at the end of the period (in shares) | 963,094 | 878,114 | |
Weighted Average Grant Date Fair Value | |||
Outstanding at the beginning of the period (in dollars per share) | $ 107.18 | ||
Granted (in dollars per share) | 92.31 | $ 147.81 | |
Released (in dollars per share) | 93.22 | ||
Forfeited (in dollars per share) | 94.30 | ||
Outstanding at the end of the period (in dollars per share) | $ 104.90 | $ 107.18 | |
Fair value of equity instruments other than options vested in period | $ 27,200,000 | $ 0 | |
Number of outstanding performance share units (in shares) | 259,865 | ||
Stock Plans | |||
Shares | |||
Outstanding at the beginning of the period (in shares) | 2,284,276 | ||
Granted (in shares) | 0 | ||
Exercised (in shares) | (485,653) | ||
Forfeited (in shares) | (8,571) | ||
Outstanding at the end of the period (in shares) | 1,790,052 | 2,284,276 | |
Vested and expected to vest at end of period (in shares) | 1,790,052 | ||
Exercisable at the end of the period (in shares) | 1,509,645 | ||
Weighted Average Exercise Price | |||
Outstanding at the beginning of the period (in dollars per share) | $ 34.65 | ||
Granted (in dollars per share) | 0 | ||
Exercised (in dollars per share) | 8.84 | ||
Forfeited (in dollars per share) | 86.02 | ||
Outstanding at the end of the period (in dollars per share) | 41.41 | $ 34.65 | |
Vested and expected to vest at end of period (in dollars per share) | 41.41 | ||
Exercisable at the end of the period (in dollars per share) | $ 36.47 | ||
Weighted Average Remaining Contractual Term | |||
Outstanding | 5 years 9 months 18 days | 5 years 6 months | |
Vested and expected to vest at end of period | 5 years 9 months 18 days | ||
Exercisable at the end of the period | 5 years 4 months 24 days | ||
Aggregate Intrinsic Value | |||
Outstanding at the end of the period | $ 63,737,000 | ||
Vested and expected to vest at end of period | 63,737,000 | ||
Exercisable at the end of the period | 58,202,000 | ||
Total intrinsic value of options exercised | $ 29,600,000 | $ 126,000,000 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 8,097 | $ 5,558 |
Operating cash flows from finance leases | 211 | 248 |
Finance cash flows from finance leases | 1,548 | 1,203 |
Non-cash investing and financing activities: | ||
Right-of-use assets obtained in exchange for new operating lease liabilities | 4,259 | 40,406 |
Right-of-use assets obtained in exchange for new finance lease liabilities | $ 878 | $ 639 |
Operating lease, weighted average lease term remaining | 8 years 2 months 1 day | 8 years 8 months 8 days |
Finance lease, weighted average remaining lease term | 2 years 9 months 18 days | 3 years 5 months 12 days |
Operating lease, weighted average discount rate | 6.09% | 6.41% |
Finance lease, weighted average discount rate | 5.32% | 5.66% |
Thrive | ||
Non-cash investing and financing activities: | ||
Right-of-use assets obtained in exchange for new operating lease liabilities | $ 39,600 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 |
Lessee, Lease, Description [Line Items] | |||
Operating lease right-of-use assets | $ 170,373 | $ 174,225 | |
Additional amount to be recognized at lease commencement for the lease liability | 200,300 | 201,900 | |
Operating lease liability, current | 19,711 | 19,710 | |
Operating lease liability, noncurrent | 180,632 | 182,166 | |
Finance lease, right-of-use asset | $ 17,400 | 18,200 | |
Finance lease, right-of-use asset, statement of financial position, extensible list | Other long-term assets, net | ||
Finance lease liability | $ 18,000 | 18,700 | |
Finance lease liability, current | $ 6,400 | $ 6,200 | |
Finance lease, liability, current, statement of financial position, extensible list | Other current liabilities | Other current liabilities | |
Finance lease liability, noncurrent | $ 11,600 | $ 12,500 | |
Finance lease, liability, noncurrent, statement of financial position, extensible list | Other long-term liabilities | Other long-term liabilities | |
DOS Rule Investigation | |||
Lessee, Lease, Description [Line Items] | |||
Estimated civil damages | $ 48,200 | ||
Loss Contingency Accrual | $ 10,000 |
WISCONSIN ECONOMIC DEVELOPMEN_2
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Feb. 28, 2015USD ($)employee | Mar. 31, 2022USD ($) | Dec. 31, 2021USD ($)position | |
Wisconsin Economic Development Tax Credit Agreement | |||
Agreements | |||
Refundable tax credits available, contingent | $ 9 | ||
Capital investment expenditures over specified period, requirement to earn the refundable tax credits | $ 26.3 | ||
Full-time positions that must be created over a specified time period to earn the refundable tax credits | employee | 758 | ||
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed | 7 years | ||
Refundable tax credits earned | $ 9 | ||
Refundable tax credit received | 9 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | |||
Agreements | |||
Capital investment expenditures over specified period, requirement to earn the refundable tax credits | $ 350 | ||
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position | 1,300 | ||
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed | 5 years | ||
Refundable tax credits earned | 9 | $ 18.5 | |
Credit earning rate | 10.00% | ||
Maximum credits available to earn | $ 7 | ||
Refundable tax credit receivable | 9 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | Operating Expense | |||
Agreements | |||
Amortization of tax credits | 1 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | Prepaid expenses and other current assets | |||
Agreements | |||
Refundable tax credit receivable | 1.7 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | Other long-term assets | |||
Agreements | |||
Refundable tax credit receivable | $ 7.3 |
BUSINESS COMBINATIONS AND ASS_2
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) - test | Dec. 31, 2021 | Jun. 23, 2021 | May 03, 2021 |
PreventionGenetics LLC | |||
Business Acquisition [Line Items] | |||
Number of tests provided | 5,000 | ||
PFS Genomics | |||
Business Acquisition [Line Items] | |||
Percent of equity acquired | 10.00% | 90.00% |
SEGMENT INFORMATION (Details)
SEGMENT INFORMATION (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022USD ($)segment | Mar. 31, 2021USD ($) | |
Segment Reporting, Revenue Reconciling Item [Line Items] | ||
Number of operating segments | segment | 1 | |
Revenue | $ 486,571 | $ 402,077 |
United States | ||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||
Revenue | 457,128 | 376,021 |
Outside of United States | ||
Segment Reporting, Revenue Reconciling Item [Line Items] | ||
Revenue | $ 29,443 | $ 26,056 |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Tax expense (benefit) | $ (2,015) | $ (242,805) | |
Deferred tax liabilities, net | 26,400 | ||
Unrecognized tax benefits | $ 23,100 | $ 21,800 |